Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y.

Oncotarget. 2019 Feb 12;10(13):1344. doi: 10.18632/oncotarget.26685. eCollection 2019 Feb 12.

2.

Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry.

Kalaora S, Samuels Y.

Methods Mol Biol. 2019;1884:203-214. doi: 10.1007/978-1-4939-8885-3_14.

PMID:
30465205
3.

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.

Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y.

Cancer Discov. 2018 Nov;8(11):1366-1375. doi: 10.1158/2159-8290.CD-17-1418. Epub 2018 Sep 12.

4.

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y.

Oncotarget. 2018 Jul 27;9(58):31264-31277. doi: 10.18632/oncotarget.25805. eCollection 2018 Jul 27. Erratum in: Oncotarget. 2019 Feb 12;10(13):1344.

5.

Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures.

Lee JS, Adler L, Karathia H, Carmel N, Rabinovich S, Auslander N, Keshet R, Stettner N, Silberman A, Agemy L, Helbling D, Eilam R, Sun Q, Brandis A, Malitsky S, Itkin M, Weiss H, Pinto S, Kalaora S, Levy R, Barnea E, Admon A, Dimmock D, Stern-Ginossar N, Scherz A, Nagamani SCS, Unda M, Wilson DM 3rd, Elhasid R, Carracedo A, Samuels Y, Hannenhalli S, Ruppin E, Erez A.

Cell. 2018 Sep 6;174(6):1559-1570.e22. doi: 10.1016/j.cell.2018.07.019. Epub 2018 Aug 9.

PMID:
30100185
6.

Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.

Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, Samuels Y.

Oncotarget. 2016 Feb 2;7(5):5110-7. doi: 10.18632/oncotarget.6960.

Supplemental Content

Loading ...
Support Center